Effect of Levosimendan on miRNAs Regulation in the Failing Hearts

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 136 participants.

Also called NCT04950569

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 136 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04950569
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04950569. Randomized; no masking; primary purpose treatment. Start 2020-10-29 (actual); primary completion 2022-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Levosimendan on miRNAs Regulation in the Failing Hearts
Condition
Heart Failure
Intervention (Drug)
levosimendan
Lead sponsor
Tongji Hospital (class: other)

Record details

Record id
cardio:ct-nct04950569
Content hash
c8a2ad066b4782a21f4f1e883e2bace36a8deebaa0a46447935f7238cb0b4009